SNBP News

Sun BioPharma, a clinical-stage biotech developing small molecule therapies for pancreatic cancer, revised the terms of its upcoming IPO on Thursday. The Waconia, MN-based company now plans to raise $11 million by offering 2.1 million shares at $5, below the last close of its shares on the OTCQB (SNBP). The company had previously filed to offer 1.1 million shares at $8.75,...read more

Sun BioPharma, a clinical-stage biotech developing small molecule therapies for pancreatic cancer, announced terms for its IPO on Thursday. The Waconia, MN-based company plans to raise $10 million by offering 1.1 million shares at $8.75, the last close of its shares on the OTCQB (SNBP). The company is also offering warrants to purchase 1.1 million shares at an assumed exercise...read more

Three IPOs raised $2.3 billion this past week, led by Dun & Bradstreet's (DNB) billion-dollar deal. All three IPOs upsized their deals and priced above the range. Commercial data analytics provider Dun & Bradstreet (DNB) raised $1.7 billion at a $9 billion market cap. The long-standing company was taken private in February 2019 by a consortium led by...read more

Sun BioPharma, a clinical-stage biotech developing small molecule therapies for pancreatic cancer, filed on Thursday with the SEC to raise up to $12 million in an initial public offering. The company is currently listed on the OTCQB (SNBP) and has a market cap of $42 million. The company's lead candidate, SBP-101, is a small molecule polyamine metabolic inhibitor delivered...read more